TD Cowen Maintains Buy Rating on Amgen With Target Price at $452

TD Cowen analyst Yaron Werber has reaffirmed his 'Buy' rating for Amgen (AMGN.US), maintaining a target price of $452. This recommendation is based on Werber's past performance, with an impressive success rate of 58.5% and an average return of 26.7% over the past year.

According to TipRanks data, which provides analysis from financial analysts, Werber has demonstrated a strong track record in his predictions. The analyst's virtual portfolio has earned positive returns from Amgen stock, further solidifying his confidence in the pharmaceutical company's growth potential.